CANDIDATE: Stuart A. Scott, Ph.D., is a clinical molecular geneticist in the Mount Sinai Genetic Testing Laboratory, certified by the American Board of Medical Genetics (ABMG), who has drawn on his training and experience in clinical and basic science to develop a research program focused on translational pharmacogenomics. His previous pharmacogenetics research centered on the anticoagulant warfarin and the antiplatelet clopidogrel, and he has co-authored clinical pharmacogenetic practice guidelines for both of these agents. He now seeks a focused four-year K23 Award to support 85% protected time from his clinical responsibilities to initiate a whole-exome sequencing pharmacogenomics research project with related career development as he completes his two-year Institutional KL2 Faculty Scholar award in translational science. CAREER DEVELOPMENT: The long-term goal of the Candidate is to become an independently funded Principal Investigator in the field of translational pharmacogenomics research. This goal will be accomplished through Clinical and Translational Science Award (CTSA)/Pharmacogenomics Research Network (PGRN)- based co-mentorship, collaboration, and the practical and didactic mechanisms outlined in this application. INSTITUTIONAL ENVIRONMENT: The Department of Genetics and Genomic Sciences at the Mount Sinai School of Medicine (MSSM) is a hybrid basic science and clinical department that offers a broad-based program of instruction, research, and clinical services in translational genetics and genomic sciences. The MSSM Institute for Genomics and Multiscale Biology is a central resource for all the equipment and computational support necessary to accomplish modern genomics research. As such, the institutional environment at MSSM is ideal for the proper execution of the studies outlined in this application. RESEARCH PROJECT: Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is standard of care for patients with acute coronary syndromes (ACS) and/or for those undergoing percutaneous coronary intervention (PCI)~ however, substantial interindividual variability in platelet inhibition and clinical response is commonly observed. Cytochrome P450-2C19 (CYP2C19) is a key enzyme involved in clopidogrel bioactivation and patients who carry CYP2C19 loss-of-function alleles have reduced therapeutic efficacy and increased risks for serious adverse cardiovascular events. However, CYP2C19 only accounts for ~12% of the variability in clopidogrel response. The proposed research project will use whole-exome sequencing and genome-wide genotyping in carefully selected extreme phenotype cohorts of DAPT-treated ACS/PCI patients to identify novel genetic variants, which could facilitate the adoption of genetically guided antiplatelet therapy into routine interventional cardiology practice for more personalized and effective care. The identification of additioal genes and variants will not only influence the uptake of personalized antiplatelet therapy, but could provide a benchmark for other pharmacogenomic studies on drugs and medications with variable responses.

Public Health Relevance

Antiplatelet responses to clopidogrel are highly variable and many patients experience serious adverse events while on treatment. Given that some of the new antiplatelet drugs have contraindications and that clopidogrel recently has come off of patent protection, clopidogrel continues to be very commonly prescribed. Identifying additional important genes and variants involved in clopidogrel response variability beyond CYP2C19 will increase the utility of genetic testing for personalized antiplatelet therapy and could ultimately help guide the implementation of future pharmacogenetic tests for additional drugs with variable responses.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
Application #
Study Section
Genetics of Health and Disease Study Section (GHD)
Program Officer
Long, Rochelle M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
Schools of Medicine
New York
United States
Zip Code
Qiao, W; Wang, J; Pullman, B S et al. (2016) The CYP2D6 VCF Translator. Pharmacogenomics J :
Kalman, L V; Agúndez, Jag; Appell, M Lindqvist et al. (2016) Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharmacol Ther 99:172-85
Scott, S A; Collet, J-P; Baber, U et al. (2016) Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. Clin Pharmacol Ther 100:287-94
Van Driest, Sara L; Wells, Quinn S; Stallings, Sarah et al. (2016) Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic Medical Records. JAMA 315:47-57
Qiao, Wanqiong; Yang, Yao; Sebra, Robert et al. (2016) Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6. Hum Mutat 37:315-23
Caudle, Kelly E; Dunnenberger, Henry M; Freimuth, Robert R et al. (2016) Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med :
Ruderfer, Douglas M; Charney, Alexander W; Readhead, Ben et al. (2016) Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry 3:350-7
Weisfeld-Adams, James D; Tkachuk, Amanda K; Maclean, Kenneth N et al. (2016) A de novo 2.78-Mb duplication on chromosome 21q22.11 implicates candidate genes in the partial trisomy 21 phenotype. NPJ Genom Med 1:
Pratt, Victoria M; Everts, Robin E; Aggarwal, Praful et al. (2016) Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project. J Mol Diagn 18:109-23
Zhang, Jinglan; Fedick, Anastasia; Wasserman, Stephanie et al. (2016) Analytical Validation of a Personalized Medicine APOL1 Genotyping Assay for Nondiabetic Chronic Kidney Disease Risk Assessment. J Mol Diagn 18:260-6

Showing the most recent 10 out of 21 publications